Summary:
- Pelage Pharmaceuticals, a biotech company, has raised $120 million in a Series B financing round to develop regenerative medicine treatments for hair loss.
- The company's focus is on developing innovative therapies that can stimulate the regrowth of hair, addressing a common problem that affects millions of people worldwide.
- The funding will be used to advance the company's research and clinical trials, with the goal of bringing new and effective hair loss treatments to the market.